Drug intelligence / Profile preview

Chai Gui granules

Development stage: Unknown
Lead developer: Shanxi University
Administration: Oral

Overview

Chai Gui granules is a traditional Chinese medicine (TCM) formulation developed by Shanxi University for the treatment of mild to moderate major depressive disorder (MDD). The formulation is specifically designed to address the TCM pattern of liver qi stagnation and spleen deficiency. It is a multi-herb granule product that has been evaluated in randomized, double-blind, placebo-controlled Phase II clinical trials in China (e.g., CTR20211955) to assess its efficacy and safety in outpatients. As a complex herbal mixture, its therapeutic effects are thought to involve the modulation of multiple pathways related to mood regulation and stress response, though specific molecular targets are not typically defined in the clinical trial context.

Other names: Chai Gui Keli

Beyond the preview

Go deeper on Chai Gui granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chai Gui granules.

Explore the full profile